Novo Holdings’ Principal Investments Provides Update on a Record Year

  • Deployed close to EUR 1.9 billion of equity*
  • Expanded portfolio to 18 companies, including new investments in Altasciences, BBI, Availity, Esco LifeSciences Group, Medical Knowledge Group and The Ritedose Corporation*
  • Increased the Principal Investments’ portfolio value by more than 30% to excess of EUR 10 billion*
  • Three successful (partial) exits
  • Continued team expansion and established direct presence in the US with opening of Boston office

Copenhagen, Denmark, 29 March 2022 – Principal Investments, the arm of Novo Holdings that invests in leading, well-established, growth-oriented healthcare & life science companies, today publishes its annual newsletter.

Read more…

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...

GET IN TOUCH